AU2003267156B2 - Pharmaceutical formulations of modafinil - Google Patents
Pharmaceutical formulations of modafinil Download PDFInfo
- Publication number
- AU2003267156B2 AU2003267156B2 AU2003267156A AU2003267156A AU2003267156B2 AU 2003267156 B2 AU2003267156 B2 AU 2003267156B2 AU 2003267156 A AU2003267156 A AU 2003267156A AU 2003267156 A AU2003267156 A AU 2003267156A AU 2003267156 B2 AU2003267156 B2 AU 2003267156B2
- Authority
- AU
- Australia
- Prior art keywords
- modafinil
- dose
- unit dose
- composition
- adhd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims description 182
- 229960001165 modafinil Drugs 0.000 title claims description 176
- 239000008194 pharmaceutical composition Substances 0.000 title description 14
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 33
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 description 37
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 12
- 229920002785 Croscarmellose sodium Polymers 0.000 description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000007884 disintegrant Substances 0.000 description 9
- 229960001021 lactose monohydrate Drugs 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 229940069328 povidone Drugs 0.000 description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 5
- 239000000391 magnesium silicate Substances 0.000 description 5
- 229910052919 magnesium silicate Inorganic materials 0.000 description 5
- 235000019792 magnesium silicate Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 229920003082 Povidone K 90 Polymers 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940117394 provigil Drugs 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 206010013486 Distractibility Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010016338 Feeling jittery Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41039502P | 2002-09-13 | 2002-09-13 | |
| US60/410,395 | 2002-09-13 | ||
| US10/660,058 US20040116532A1 (en) | 2002-09-13 | 2003-09-11 | Pharmaceutical formulations of modafinil |
| US10/660,058 | 2003-09-11 | ||
| PCT/US2003/028651 WO2004024134A1 (en) | 2002-09-13 | 2003-09-12 | Pharmaceutical formulations of modafinil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003267156A1 AU2003267156A1 (en) | 2004-04-30 |
| AU2003267156B2 true AU2003267156B2 (en) | 2010-03-11 |
Family
ID=32511269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003267156A Ceased AU2003267156B2 (en) | 2002-09-13 | 2003-09-12 | Pharmaceutical formulations of modafinil |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20040116532A1 (https=) |
| EP (1) | EP1539126B1 (https=) |
| JP (1) | JP5039246B2 (https=) |
| KR (1) | KR101125462B1 (https=) |
| CN (1) | CN100528151C (https=) |
| AU (1) | AU2003267156B2 (https=) |
| BR (1) | BR0314514A (https=) |
| CA (1) | CA2498260C (https=) |
| DK (1) | DK1539126T3 (https=) |
| EA (1) | EA012964B1 (https=) |
| ES (1) | ES2392580T3 (https=) |
| IL (1) | IL167054A (https=) |
| IS (1) | IS2871B (https=) |
| MX (1) | MXPA05002827A (https=) |
| NO (1) | NO333614B1 (https=) |
| NZ (1) | NZ538941A (https=) |
| PL (1) | PL375833A1 (https=) |
| PT (1) | PT1539126E (https=) |
| SI (1) | SI1539126T1 (https=) |
| TW (1) | TWI335217B (https=) |
| WO (1) | WO2004024134A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2277937T3 (es) | 2000-07-27 | 2007-08-01 | Teva Pharmaceutical Industries Ltd. | Modafinilo puro y cristalino y su procedimiento de preparacion. |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| DK1610796T3 (da) * | 2003-03-17 | 2014-07-21 | Neurohealing Pharmaceuticals Inc | Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| US8153159B2 (en) * | 2003-09-18 | 2012-04-10 | Cephalon, Inc. | Modafinil modified release pharmaceutical compositions |
| UA94380C2 (ru) * | 2003-09-18 | 2011-05-10 | Сефалон, Інк. | Фармацевтические композиции модафинила с модифицированным высвобождением |
| WO2005099822A2 (en) * | 2004-04-13 | 2005-10-27 | Cephalon, Inc. | Reduction of drug / drug interactions with modafinil |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| AU2005235422B2 (en) * | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| US20060024370A1 (en) | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| BRPI0500520A (pt) * | 2005-02-16 | 2006-09-26 | Henry Jun Suzuki | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
| WO2006096434A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| US20060264511A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| US20060264512A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunction due to medical conditions |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| CA2626134C (en) * | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| US20090023712A1 (en) * | 2006-02-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin |
| EP2037927B1 (en) * | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| WO2008006838A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| JP5793828B2 (ja) * | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| KR20090045945A (ko) * | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 제어 방출 시스템 및 이의 제조방법 |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
| CL2008002693A1 (es) * | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| FR2987265B1 (fr) * | 2012-02-28 | 2014-02-28 | Debregeas Et Associes Pharma | Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002030414A1 (en) * | 2000-10-11 | 2002-04-18 | Cephalon, Inc. | Compositions comprising modafinil compounds |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1570994A (en) | 1923-11-20 | 1926-01-26 | William A Cook | Spring-forming die |
| US3629393A (en) | 1969-09-11 | 1971-12-21 | Nikken Chemicals Co Ltd | Release-sustaining-tablet |
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| DE2927988A1 (de) | 1979-07-11 | 1981-02-05 | Thomae Gmbh Dr K | Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel |
| US4431645A (en) | 1982-03-08 | 1984-02-14 | Schering Corporation | Antihypertensive agents |
| HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
| US4584285A (en) | 1983-06-02 | 1986-04-22 | Schering Corporation | Antihypertensive agents |
| US4710519A (en) | 1985-09-30 | 1987-12-01 | Basf Corporation | Process for preparing spray dried acetaminophen powder and the powder prepared thereby |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| US5084277A (en) | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| GB9225492D0 (en) | 1992-12-05 | 1993-01-27 | Glaxo Group Ltd | Amine derivatives |
| TW272942B (https=) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
| FR2702968B1 (fr) | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
| US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| FR2706767B1 (https=) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2707637B1 (fr) * | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5506248A (en) | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| JPH09208468A (ja) * | 1996-02-02 | 1997-08-12 | Dainippon Pharmaceut Co Ltd | ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤 |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| ATE503472T1 (de) | 1996-11-15 | 2011-04-15 | Ajinomoto Kk | Nateglinide-tablettenzubereitungen |
| GB9714274D0 (en) | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
| CN1277550A (zh) | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物 |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| HUP0104606A3 (en) * | 1998-12-18 | 2003-01-28 | Basf Ag | A pharmaceutical mixture comprising a profen |
| PL356899A1 (en) | 1998-12-18 | 2004-07-12 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| CN1249932A (zh) * | 1999-09-29 | 2000-04-12 | 付俊昌 | 一种莫达芬尼及其光学对映体l及d异构体的新用途 |
| FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
| US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| CA2425338C (en) | 2000-10-11 | 2010-04-20 | Cephalon, Inc. | Compositions comprising modafinil compounds |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7297346B2 (en) | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7576133B2 (en) * | 2002-03-11 | 2009-08-18 | Carl Henry Lawyer | Methods and compositions for nasal administration of modafinil |
| US7229644B2 (en) | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US7115281B2 (en) | 2002-07-08 | 2006-10-03 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
| EP1526842A1 (en) | 2002-07-25 | 2005-05-04 | Ranbaxy Laboratories, Ltd. | Processes for the preparation of oral dosage formulations of modafinil |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
-
2003
- 2003-09-11 US US10/660,058 patent/US20040116532A1/en not_active Abandoned
- 2003-09-12 PT PT03749630T patent/PT1539126E/pt unknown
- 2003-09-12 SI SI200332193T patent/SI1539126T1/sl unknown
- 2003-09-12 DK DK03749630.4T patent/DK1539126T3/da active
- 2003-09-12 ES ES03749630T patent/ES2392580T3/es not_active Expired - Lifetime
- 2003-09-12 WO PCT/US2003/028651 patent/WO2004024134A1/en not_active Ceased
- 2003-09-12 NZ NZ538941A patent/NZ538941A/en not_active IP Right Cessation
- 2003-09-12 CN CNB03821749XA patent/CN100528151C/zh not_active Expired - Fee Related
- 2003-09-12 PL PL03375833A patent/PL375833A1/xx not_active Application Discontinuation
- 2003-09-12 BR BR0314514-0A patent/BR0314514A/pt not_active IP Right Cessation
- 2003-09-12 CA CA2498260A patent/CA2498260C/en not_active Expired - Fee Related
- 2003-09-12 MX MXPA05002827A patent/MXPA05002827A/es active IP Right Grant
- 2003-09-12 KR KR1020057004198A patent/KR101125462B1/ko not_active Expired - Fee Related
- 2003-09-12 AU AU2003267156A patent/AU2003267156B2/en not_active Ceased
- 2003-09-12 JP JP2004536184A patent/JP5039246B2/ja not_active Expired - Fee Related
- 2003-09-12 EP EP03749630A patent/EP1539126B1/en not_active Expired - Lifetime
- 2003-09-12 EA EA200500488A patent/EA012964B1/ru not_active IP Right Cessation
- 2003-09-15 TW TW092125314A patent/TWI335217B/zh not_active IP Right Cessation
-
2005
- 2005-02-22 IL IL167054A patent/IL167054A/en not_active IP Right Cessation
- 2005-02-24 IS IS7714A patent/IS2871B/is unknown
- 2005-02-28 NO NO20051079A patent/NO333614B1/no not_active IP Right Cessation
-
2008
- 2008-04-24 US US12/150,056 patent/US8268892B2/en not_active Expired - Fee Related
-
2012
- 2012-08-21 US US13/590,912 patent/US8859621B2/en not_active Expired - Fee Related
- 2012-08-21 US US13/590,865 patent/US8686047B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002030414A1 (en) * | 2000-10-11 | 2002-04-18 | Cephalon, Inc. | Compositions comprising modafinil compounds |
Non-Patent Citations (2)
| Title |
|---|
| D2: WONG et al, J. Clin. Pharmacol., vol. 39, no. 1, January 1999, pp 30-40 * |
| D3: RUGINO et al J. Am. Acad. Child Adolesc. Psychiatry, vol. 40, no. 2, February 2001, pp 230-235 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003267156B2 (en) | Pharmaceutical formulations of modafinil | |
| EP1397127B1 (en) | Solid pharmaceutucal formulations comprising modafinil | |
| US9433602B2 (en) | Combination and composition for treating obesity | |
| ZA200502789B (en) | Pharmaceutical formulations of modafinil | |
| HK1076734B (en) | Tablets containing 250 to 450 mg of modafinil | |
| US20080058345A1 (en) | Combination Therapy with Mecamylamine for the Treatment of Mood Disorders | |
| EP3996699B1 (en) | Combination of ibuprofen and tramadol for relieving pain | |
| INC | Pr AA-LEVOCARB CR | |
| HK40067137A (en) | Combination of ibuprofen and tramadol for relieving pain | |
| Tablets et al. | Pr Sandoz Naratriptan | |
| HK1061652B (en) | Solid pharmaceutical formulations comprising modafinil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CEPHALON, INC. Free format text: FORMER APPLICANT(S): PARIKH, ALPA; HEACOCK, CRAIG; CEPHALON, INC.; PATEL, PIYUSH |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |